Cargando…

Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions

BACKGROUND: Cutaneous adverse drug reactions (CADRs) are probably the most frequent of all manifestations of drug sensitivity. As a considerable number of new drugs are periodically introduced into the market, the incidence of CADR is likely to increase. The pattern of CADR and the causative drugs i...

Descripción completa

Detalles Bibliográficos
Autores principales: Beniwal, Ranjana, Gupta, Lalit Kumar, Khare, Ashok Kumar, Mittal, Asit, Mehta, Sharad, Balai, Manisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362752/
https://www.ncbi.nlm.nih.gov/pubmed/30775295
http://dx.doi.org/10.4103/idoj.IDOJ_207_18
_version_ 1783392992557531136
author Beniwal, Ranjana
Gupta, Lalit Kumar
Khare, Ashok Kumar
Mittal, Asit
Mehta, Sharad
Balai, Manisha
author_facet Beniwal, Ranjana
Gupta, Lalit Kumar
Khare, Ashok Kumar
Mittal, Asit
Mehta, Sharad
Balai, Manisha
author_sort Beniwal, Ranjana
collection PubMed
description BACKGROUND: Cutaneous adverse drug reactions (CADRs) are probably the most frequent of all manifestations of drug sensitivity. As a considerable number of new drugs are periodically introduced into the market, the incidence of CADR is likely to increase. The pattern of CADR and the causative drugs is likely to change accordingly. There is no uniformly accepted and reliable method of objectively assessing the causal link between drug and adverse reaction. AIM: To study the clinical patterns and causative drugs and compare causality assessment [World Health Organization (WHO) and Naranjo algorithm] of CADR among patients attending the dermatology department. MATERIALS AND METHODS: This is a cross-sectional hospital-based study in which all patients with suspected CADR attending the dermatology department of a tertiary care center over a 9-month period were evaluated using the causality assessment criteria recommended by the WHO-Uppsala Monitoring Centre (UMC) and Naranjo scale. The severity of the reaction was assessed using Adverse Drug Reaction Severity Assessment Scale (modified Hartwig and Siegel scale). RESULTS: A total of 200 consecutive patients with CADR were evaluated. The causality assessment for a drug as per WHO scale yielded 63 (31.5%) cases as certain, 12 (6%) as probable, and 125 (62.5%) as possible, whereas Naranjo scale showed 26 (13%) cases to be definite, 138 (69%) as probable, and 36 (18%) as possible. There was poor agreement between the two scales. Fixed drug eruption was the most common pattern of CADR (82.41%). The average number of drugs received by patients was 2.09. The most common suspected drug group was antimicrobials (n = 170; 40.5%), followed by nonsteroidal anti-inflammatory drugs (n = 148; 35.3%) and antiretroviral drugs (n = 41; 9.7%). Fixed drug eruption was most commonly caused by paracetamol. Antiepileptics and antimicrobials were the most common suspects among severe cutaneous adverse reactions. LIMITATIONS: Multiple concomitant drug usage by patients and inability to provoke all patients/measure drug levels in blood resulted in higher number of drugs with causal association as probable/possible. CONCLUSION: WHO-UMC scale was found to be easier to apply and evaluate, with greater practical utility. Poor agreement between the two commonly used scales emphasizes the need for a consistent and uniform causality assessment tool.
format Online
Article
Text
id pubmed-6362752
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-63627522019-02-17 Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions Beniwal, Ranjana Gupta, Lalit Kumar Khare, Ashok Kumar Mittal, Asit Mehta, Sharad Balai, Manisha Indian Dermatol Online J Original Article BACKGROUND: Cutaneous adverse drug reactions (CADRs) are probably the most frequent of all manifestations of drug sensitivity. As a considerable number of new drugs are periodically introduced into the market, the incidence of CADR is likely to increase. The pattern of CADR and the causative drugs is likely to change accordingly. There is no uniformly accepted and reliable method of objectively assessing the causal link between drug and adverse reaction. AIM: To study the clinical patterns and causative drugs and compare causality assessment [World Health Organization (WHO) and Naranjo algorithm] of CADR among patients attending the dermatology department. MATERIALS AND METHODS: This is a cross-sectional hospital-based study in which all patients with suspected CADR attending the dermatology department of a tertiary care center over a 9-month period were evaluated using the causality assessment criteria recommended by the WHO-Uppsala Monitoring Centre (UMC) and Naranjo scale. The severity of the reaction was assessed using Adverse Drug Reaction Severity Assessment Scale (modified Hartwig and Siegel scale). RESULTS: A total of 200 consecutive patients with CADR were evaluated. The causality assessment for a drug as per WHO scale yielded 63 (31.5%) cases as certain, 12 (6%) as probable, and 125 (62.5%) as possible, whereas Naranjo scale showed 26 (13%) cases to be definite, 138 (69%) as probable, and 36 (18%) as possible. There was poor agreement between the two scales. Fixed drug eruption was the most common pattern of CADR (82.41%). The average number of drugs received by patients was 2.09. The most common suspected drug group was antimicrobials (n = 170; 40.5%), followed by nonsteroidal anti-inflammatory drugs (n = 148; 35.3%) and antiretroviral drugs (n = 41; 9.7%). Fixed drug eruption was most commonly caused by paracetamol. Antiepileptics and antimicrobials were the most common suspects among severe cutaneous adverse reactions. LIMITATIONS: Multiple concomitant drug usage by patients and inability to provoke all patients/measure drug levels in blood resulted in higher number of drugs with causal association as probable/possible. CONCLUSION: WHO-UMC scale was found to be easier to apply and evaluate, with greater practical utility. Poor agreement between the two commonly used scales emphasizes the need for a consistent and uniform causality assessment tool. Medknow Publications & Media Pvt Ltd 2019 /pmc/articles/PMC6362752/ /pubmed/30775295 http://dx.doi.org/10.4103/idoj.IDOJ_207_18 Text en Copyright: © 2019 Indian Dermatology Online Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Beniwal, Ranjana
Gupta, Lalit Kumar
Khare, Ashok Kumar
Mittal, Asit
Mehta, Sharad
Balai, Manisha
Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions
title Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions
title_full Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions
title_fullStr Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions
title_full_unstemmed Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions
title_short Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions
title_sort clinical profile and comparison of causality assessment tools in cutaneous adverse drug reactions
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362752/
https://www.ncbi.nlm.nih.gov/pubmed/30775295
http://dx.doi.org/10.4103/idoj.IDOJ_207_18
work_keys_str_mv AT beniwalranjana clinicalprofileandcomparisonofcausalityassessmenttoolsincutaneousadversedrugreactions
AT guptalalitkumar clinicalprofileandcomparisonofcausalityassessmenttoolsincutaneousadversedrugreactions
AT khareashokkumar clinicalprofileandcomparisonofcausalityassessmenttoolsincutaneousadversedrugreactions
AT mittalasit clinicalprofileandcomparisonofcausalityassessmenttoolsincutaneousadversedrugreactions
AT mehtasharad clinicalprofileandcomparisonofcausalityassessmenttoolsincutaneousadversedrugreactions
AT balaimanisha clinicalprofileandcomparisonofcausalityassessmenttoolsincutaneousadversedrugreactions